Skip to main content

VISTA, PHASE 3 TRIAL OF VICINIUM, AN EPCAM-TARGETED PSEUDOMONAS EXOTOXIN, IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER

Dickstein
Rian
Bladder Cancer Program
Chesapeake Urology
Baltimore
MD
USA
Show all authors
Wu
Ning
Comprehensive Urologic Care
Elgin
Illinois
USA
Cowan
Barrett
Urology Associates
Englewood
CO
USA
Dunshee
Curt
Urological Associates of Southern Arizona
Tucson
AZ
USA
Franks
Michael
Virginia Urology
Stony Point
Virginia
USA
Wolk
Fred
Sky Urology
Torrance
CA
USA
Belkoff
Laurence
Urologic Consultants of Southeastern Pennsylvania
Bala Cynwyd
PA
USA
Castellucci
Sean
Urology Partners
Bradenton
FL
USA
Holzbeierlein
Jeffrey
Univ of Kansas Med. Center
Kansas City
Kansas
USA
Kulkarni
Girish
Division of Urology
Princess Margaret Cancer Centre
Toronto
Canada
Weizer
Alon
U of M Urology Cancer Center
Ann Arbor
MI
USA
Lamm
Donald
BCG Oncology
Phoeniz
AZ
USA
Ali
Syed
Pathology
Johns Hopkins Medical Center
Baltimore
MD
USA
Epstein
Jonathan
Pathology
Johns Hopkins Medical Center
Baltimore
MD
USA
Adams
Gregory
Sesen Bio
Philadelphia
PA
USA
Youssoufian
Hagop
Sesen Bio
Cambridge
MA
USA
Kassouf
Wassim
McGill University Health Center
Montreal
Quebec
Canada

Tabs

Speciality: 
Urology
Keywords: 
bladder cancer, non-muscle invasive bladder cancer, Clinical trial, Drug therapy, Biomarker, antibody